Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18621797 | 0.98 | DPP4 (1.00) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL6596202 | 0.98 | DPP4 (0.97) | DPP4DPP8DPP9 | |
| SCHEMBL13417345 | 0.98 | DPP4 (1.00) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3195551 | 0.94 | DPP4 (0.97) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3195546 | 0.94 | DPP4 (0.97) | DPP4DPP8DPP9 | |
| SCHEMBL13417344 | 0.89 | DPP4 (0.86) | DPP4DPP8DPP9 | |
| SCHEMBL3815997 | 0.89 | DPP4 (0.82) | DPP4DPP8DPP9 | |
| SCHEMBL3815993 | 0.89 | DPP4 (0.82) | DPP4DPP8DPP9 | |
| SCHEMBL5103839 | 0.88 | DPP4 (0.80) | DPP4DPP8DPP9 | |
| SCHEMBL3661389 | 0.88 | DPP4 (0.84) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893103-B2 | Dipeptidyl peptidase IV (DPP-IV); industrial scale process of making antidiabetics such as (2S,4S)-1-{2-[(3SR,1RS)-3-(1H-1,2,4-Triazol-1-ylmethyl)cyclopentylamino]acetyl}-4-fluoro-pyrrolidine-2-carbonitrile starting from ethyl glyoxalate and 3-(1H-1,2,4-triazol-1-ylmethyl)cyclopententylamine for example | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-02-22 | — | — | US | disclosed |
| US-20080076818-A1 | NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-03-27 | — | — | US | disclosed |
| WO-2006040625-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076818-A1 | NOVEL PROCESSES FOR THE PREPARATION OF DPP IV INHIBITORS | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.